NanoCor Therapeutics

NanoCor Therapeutics develops viable intracellular genetic protein therapy for the treatment of chronic heart failure.

NanoCor Therapeutics is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF). The company was spun off from Asklêpios BioPharmaceutical, Inc. in November 2005. NanoCorâ€s initial focus is the commercial development of a non-invasive treatment for CHF. NanoCorâ€s therapeutic is comprised of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBioâ€s proprietary Biological NanoParticle (BNPâ„¢) and the Self-Complementary Vector technologies, which are derived from human adeno-associated virus vectors (rAAV).